In the field of innovative treatments for type 2 diabetes, tirzepatide emerges as a novel dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. This drug, designed for weekly subcutaneous administration, has shown promising results in some clinical trials such as reduction in hemoglobin A1c and body weight in patients with type 2 diabetes, even outperforming selective GLP-1 receptor agonists [1]. Although both leptin and adiponectin are fundamental in regulating metabolism and are involved in the pathogenesis of obesity and type 2 diabetes, the effects of tirzepatide on these adipokines have not been explored.
